What was the main purpose of this 8-K filing?

This 8-K filing was made to report the official voting results from Boston Scientific Corporation's 2016 Annual Meeting of Stockholders, which included the election of directors, an advisory vote on executive compensation, and the ratification of the independent auditor.

How did shareholders vote on the director nominees?

Shareholders overwhelmingly approved all ten director nominees. The "For" votes for each nominee were well over 1 billion, with very low numbers of "Withheld" votes, indicating strong shareholder confidence in the board's composition.

Was the executive compensation approved by shareholders?

Yes, the advisory vote on the compensation for Boston Scientific's Named Executive Officers received approval from shareholders, with a significant majority voting in favor.

What is the significance of re-approving the Long-Term Incentive Plan performance goals?

Re-approving the material terms of performance goals under the Long-Term Incentive Plan is important for ensuring that compensation paid under the plan to executives remains tax-deductible for the company under Section 162(m) of the Internal Revenue Code. This preserves the value of compensation arrangements for both the company and its executives.

BSX 8-K: Shareholder Matters

Summary

This 8-K filing by Boston Scientific Corporation (BSX) reports on the outcomes of their 2016 Annual Meeting of Stockholders held on May 3, 2016. The primary focus of the filing is the voting results on key corporate matters, which generally showed strong support from shareholders. All ten director nominees were overwhelmingly elected for a one-year term, indicating confidence in the current board leadership. Additionally, shareholders approved the advisory vote on executive compensation for Named Executive Officers and re-approved the material terms of performance goals for the 2011 Long-Term Incentive Plan, crucial for tax deductibility under Section 162(m) of the IRS code. The appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2016 also received strong ratification. These results suggest a stable governance environment and shareholder alignment on executive pay and audit oversight. For investors, the overwhelming approval of director nominees and executive compensation proposals signals a well-governed company with shareholder confidence in its leadership and compensation structure. The re-approval of the Long-Term Incentive Plan's performance goals is essential for maintaining the company's ability to incentivize and retain key executives while ensuring tax efficiency. The ratification of the auditor appointment provides assurance regarding financial reporting and oversight. Overall, the outcomes of the annual meeting presented in this 8-K are positive and indicate strong shareholder support for Boston Scientific's current operations and governance.

Key Highlights

1All ten director nominees were elected to the Board of Directors with substantial majority votes.
2The advisory vote on the compensation of the Company's Named Executive Officers was approved.
3Shareholders re-approved the material terms of performance goals under the 2011 Long-Term Incentive Plan for Section 162(m) purposes.
4The appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2016 was ratified.
5The Annual Meeting of Stockholders took place on May 3, 2016, at the company's Corporate Headquarters.
6Director votes showed very high "For" percentages, with minimal "Withheld" votes and a consistent number of "Broker Non-Votes" across all nominees.

BOSTON SCIENTIFIC CORP 8-K Report, Shareholder Vote Results (May 5, 2016)

Summary

Key Highlights

Frequently Asked Questions